Now you can buy Vaniqa delivered right to your door.
Pharma-Supplies pledges for the lowest cost pharmaceutical supplies, prescsription drugs and medications (Let us know if you know of cheaper places and we'll try to match).
Generic Names: Elornithine , Generic VaniqaBrand names: Vaniqa
| Product | Qty | Price | Medical Fees & Shipping | Price/ Qty | Click to Order |
|---|---|---|---|---|---|
| View all available Vaniqa dosages | |||||
| Vaniqa 13.90% 30gm | 1 | $116.00 | $15.00 | $116.00 | Buy from RxPayouts |
| Vaniqa 13.90% 30gm | 3 | $347.00 | $15.00 | $115.67 | Buy from RxPayouts |
Vaniqa 13.90% 30gm 
When buying online you have to be aware of a few things:
- All our pharmacies offer free consultation by licensed Doctors, were required.
- Some Pharmacies offer next Day Shipping or Saturday Shipping. This may cost extra.
- All shipping costs are shown before you place your order
- Private & Confidential Service, Secure Online Order Form.
Vaniqa Information
Vaniqa is an enzyme inhibitor used topically to slow the growth of unwanted facial hair (UFH(Unwanted Facial Hair)) in women. It does not remove hair. Vaniqa (eflornithine HCl) is a facial cream.
Vaniqa Ingredients and Composition
Vaniqa is a cream containing 13.9% (139 mg/g) of anhydrous eflornithine hydrochloride as eflornithine hydrochloride monohydrate (150 mg/g).
Other ingredients include: ceteareth-20, cetearyl alcohol, dimethicone, glyceryl stearate, methylparaben, mineral oil, PEG-100 stearate, phenoxyethanol, propylparaben, stearyl alcohol and water.
Vaniqa Structural Formula and Composition
Chemically, eflornithine hydrochloride is (+) -2-(difluoromethyl) ornithine monohydrochloride monohydrate, with the empirical formula C6H12F2N2O2• HCl•H2O, a molecular weight of 236.65 and the structural formula shown.
Anhydrous eflornithine hydrochloride has an empirical formula C6H12F2N2O2•HCl and a molecular weight of 218.65.
Clinical Pharmacology: Pharmacodynamics
There are no studies examining the inhibition of the enzyme ornithine decarboxylase (ODC(Ornithine Decarboxylase)) in human skin following the application of topical eflornithine. However, there are studies in the literature that report the inhibition of ODC(Ornithine Decarboxylase) activity in skin following oral eflornithine. It is postulated that topical eflornithine hydrochloride irreversibly inhibits skin ODC(Ornithine Decarboxylase) activity. This enzyme is necessary in the synthesis of polyamines. Animal data indicate that inhibition of ornithine decarboxylase inhibits cell division and synthetic functions, which affect the rate of hair growth. Vaniqa (eflornithine hydrochloride) Cream, 13.9% has been shown to retard the rate of hair growth in non-clinical and clinical studies.
Clinical Pharmacology: Pharmacokinetics
The mean percutaneous absorption of eflornithine in women with unwanted facial hair, from a 13.9% w/w cream formulation, is < 1% of the radioactive dose, following either single or multiple doses under conditions of clinical use, that included shaving within 2 hrs before radiolabeled dose application in addition to other forms of cutting or plucking and tweezing to remove facial hair. Steady state was reached within four days of twice-daily application. The apparent steady-state plasma t1/2 of eflornithine was approximately 8 hours. Following twice-daily application of 0.5 g of the cream (total dose 1.0 g/day; 139 mg as anhydrous eflornithine hydrochloride), under conditions of clinical use in women with unwanted facial hair (n=10), the steady-state Cmax, Ctrough and AUC12hr were approximately 10 ng/mL, 5 ng/mL, and 92 ng•hr/mL, respectively, expressed in terms of the anhydrous free base of eflornithine hydrochloride. At steady state, the dose-normalized peak concentrations (Cmax) and the extent of daily systemic exposure (AUC) of eflornithine following twice-daily application of 0.5 g of the cream (total dose 1.0 g/day) is estimated to be approximately 100- and 60-fold lower, when compared to 370 mg/day once-daily oral doses. This compound is not known to be metabolized and is primarily excreted unchanged in the urine.
How To Take Vaniqa and Vaniqa Dosage and Administration
Follow the directions for using this medicine provided by your doctor. This medicine comes with a patient information leaflet. Read it carefully. Ask your doctor, nurse, or pharmacist any questions that you may have about this medicine. Apply a thin layer of this medicine to the affected areas of the face and under the chin, at least 5 minutes after hair removal (e.g., plucking, shaving). Rub in thoroughly. Do not wash the treated area for at least 4 hours. Wait at least 8 hours between applications of this medicine. Do not apply 2 doses at once. Cosmetics or sunscreens may be applied after the medicine has dried.
Vaniqa Side Effects
In clinical trials with Vaniqa, some women experienced mild and temporary side effects, skin irritations such as redness, stinging, burning, tingling, skin rash or hair bumps (folliculitis). If they continue or are bothersome, check with your doctor. Contact your doctor immediately if you experience bleeding skin, or swelling of the face or lips. If you notice other effects not listed above, contact your doctor, nurse, or pharmacist.
Vaniqa is a prescription drug for external use only. Vaniqa was studied in women around the lips and under the chin.
Vaniqa Precautions and Contraindications
This medicine is not a dipilatory. You will need to continue your routine method of hair removal while using this medicine. You may not see improvement for the first month of use. If your symptoms do not improve or become worse, check with your doctor. This medicine is not for use in children under 12 years of age.
Taking Vaniqa during Pregnancy or Breast-feeding
If you plan on becoming pregnant, discuss with your doctor the benefits and risks of using this medicine during pregnancy. It is unknown if this medicine is excreted in breast milk. If you are or will be breast-feeding while you are using this medicine, check with your doctor or pharmacist to discuss the risks to your baby.
Vaniqa Drug Interactions
Inform your doctor about all the medicines you take with and without a prescription.
If You Miss a Dose of Vaniqa
If you miss a dose, skip the missed dose and resume your usual dosing schedule. Do not "double-up" the amount used to catch up.
Storing Vaniqa
Store this medicine at room temperature (77° F or 25° C) in a tightly-closed container, away from sunlight., away from heat and light. Brief storage between 59 and 86° F (15 and 30° C) is permitted.
Keep this and all medications out of the reach of children. Do not freeze.
Additional Notes
Do not share this medication with other people.
Vaniqa Clinical Trials and Studies
Results of topical dermal studies for contact sensitization, photocontact sensitization, and photocontact irritation reveal that under conditions of clinical use, Vaniqa is not expected to cause contact sensitization, phototoxic, or photosensitization reactions. Results of the topical dermal study for contact irritation did reveal that Vaniqa could cause irritation reactions in clinical use in susceptible individuals or under conditions of exaggerated use. Two randomized double-blind studies involving 594 female patients (393 treated with Vaniqa, 201 with vehicle) treated twice daily for up to 24 weeks evaluated the efficacy of
Vaniqa in the reduction of unwanted facial hair in women. Women in the trial had a customary frequency of removal of facial hair two or more times per week. Women with facial conditions such as severe inflammatory acne, women who were pregnant, and nursing mothers were excluded from the studies.
Physicians assessed the improvement or worsening from the baseline condition (Physician's Global Assessment [PGA(Physician's Global Assessment)]), 48 hours after shaving, of all treated areas. Statistically significant improvement for Vaniqa (eflornithine hydrochloride) Cream, 13.9% versus vehicle was seen in each of these studies for "marked improvement" or greater response (24-week time point; p= 0.001). Marked improvement was seen consistently at 8 weeks after initiation of treatment and continued throughout the 24 weeks of treatment. Hair growth approached pretreatment levels within 8 weeks of treatment withdrawal.
Approximately 32% of patients showed marked improvement or greater (protocol definition of clinical success) after 24 weeks of treatment with Vaniqa (eflornithine hydrochloride) Cream, 13.9%, compared to 8% with the vehicle. Combined results of these two trials through 24 weeks are presented below.
| PGA(Physician's Global Assessment) Outcome | Vaniqa | Vehicle |
| Clear/almost clear | 5% | 0% |
| Marked improvement | 27% | 8% |
| Improved | 026% | 26% |
| No improvement/worse/missing | 42% | 66% |
Subgroup analyses appeared to suggest greater benefit for Whites than non-Whites (37% vs. 22% success, respectively; p=0.017). However, non-Whites, mostly Black subjects, did have significant treatment benefit with 22% graded as success on Vaniqa compared to 5% on vehicle. About 12% of women in the clinical trials were postmenopausal. Significant improvement in PGA(Physician's Global Assessment) outcome versus vehicle was seen in postmenopausal women (38% compared to 0%, p= 0.001).
Vaniqa statistically significantly reduced how bothered patients felt by their facial hair and by the time spent removing, treating, or concealing facial hair. These patient-observable differences were seen as early as 8 weeks after initiating treatment. Hair growth approached pretreatment levels within 8 weeks of treatment withdrawal.
Clinical trials with Vaniqa involved over 1370 women with unwanted facial hair of skin types I-VI, of whom 68% were White, 17% Black, 11% Hispanic-Latino, 2% Asian-Pacific Islander, 0.6% American Native, and 1.3% other.
Experiences, Testimonials and Reviews of Vaniqa
Women of all ages and backgrounds are affected by unwanted facial hair - and in varying degrees. Whether you consider your unwanted facial hair to be a mere inconvenience or a serious problem, you're not alone.
The good news is that Vaniqa (eflornithine HCl) Cream, 13.9% has helped women like you by slowing the growth of unwanted facial hair, so over time they may be removing hair less often. Read their success stories below to find out more.
Not everyone will experience the same or similar results to treatment.
M.S, Drexel Hill, Pennsylvania:
"I was spending at least 2 ½ hours a night tweezing all the hair off my face and even then I had a five o'clock shadow by morning. After using Vaniqa for the past four months, I am down to tweezing stragglers about 10 minutes a day and I have gone 3 or 4 days without really having to do any tweezing. There is no constant stubble on my face and my husband now loves running his hands over my face (something I never would have allowed him to do before. I never let anyone touch my face.)"
C.S, Orange, California:
"I have had hair on my chin since I was 23. I'm 41 now. I have tried everything. I've been using Vaniqa around two months now and the growth of my facial hair has really slowed down. I must have had $200 worth of tweezers in every shape and size but I don't use them very often anymore."
Credits for Vaniqa Information
Vaniqa information on this page is copyright by Drug Information at Pharma-Help.com, reprinted with Permission. All Rights Reserved. Other pages with reprint permission include Vaniqa. Additional encyclopaedic information: Vaniqa.